Aurobindo Pharma Ltd NSE  /  BSE

Pharmaceuticals, Large Cap

20 Jan 2020 | 04:15 PM

482.95
-3.00 (-0.62%)

Independent Research

theScreeners

We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Star Rating

Initiated on 01-01-70

Target Price

Performance parameters

  • Earnings Revision Trend

    Analysts negative since 19-Jul-2019

    Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 19-Jul-2019 at a price of 552.40.

  • Valuation Rating

    Strongly undervalued

    Based on its growth potential and our own criteria, at its current price the stock is strongly undervalued.

  • MT Tech Trend

    Trend neutral but previously positive (since 16-Aug-2019)

    The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 16-Aug-2019), the stock traded above its moving average. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 580.996.

  • 4W REL Performance

    vs. SENSEX30

    The four week relative overperformance versus SENSEX30 is 9.870.

Risk parameters

  • Risk Zone

    Moderate

    Moderate, no change over 1 year.

  • Bear Market

    Average sensitivity to market corrections

    On average, the stock is likely to decline with the index.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 274%.

  • Beta

    100 Average sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 100%.

  • Correlation

    0.4 Weak correlation to SENSEX30

    Stock movements are strongly independent of index variations.

  • Value at Risk

    Rs.71.85 The medium term value at risk is estimated at 71.85 or 0.12010%

    The value at risk is estimated at 71.85. The risk is therefore 0.12010%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    13.11 Current year to 2021 annualized estimate

    The annualized growth estimate is for the current year to 2021.

  • P/E Ratio

    10.64 Estimated PE for 2021

    The estimated PE is for the year 2021.

  • G/PE Ratio

    1.29 30.036% discount to expected growth

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of 30.036%.

  • Dividend Yield

    0.58% Dividend is largely covered by profits

    The twelve month estimated dividend yield represents 6.147% of earnings forecasts.

  • Global Evaluation

    Slightly positive

    The stock is classified in the slightly positive zone since 20-Aug-2019.